{"slug":"api-magentlab-com-api-calc-prevail-98bad3","title":"Armstrong 2018 PREVAIL Cox linear predictor for overall survival in chemotherapy","host":"api.magentlab.com","method":"POST","resource":"https://api.magentlab.com/api/calc/prevail","category":"other","description":"Armstrong 2018 PREVAIL Cox linear predictor for overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer from albumin, ALP versus ULN, bone metastases under 10, hemoglobin, LDH versus ULN, NLR under 2.5, pain 0-1, liver metastases, ln(PSA), months from diagnosis, and en","price_listed":0.005,"price_asked":0.007,"state":"overcharges","state_label":"Asked 1.4x its listed price for its own example","checks_7d":1,"answered_7d":1,"latency_ms_median":305,"reported_calls_30d":0,"reported_payers_30d":0,"networks":["eip155:8453"],"badge":"unverified","paid_checks_7d":0,"paid_ok_7d":0,"example_input":{"body":{"items":[{"albumin_g_dl":4,"alp_below_uln":true,"bone_mets_lt_10":true,"hemoglobin_g_dl":13,"ldh_below_uln":true,"months_since_diagnosis":60,"nlr_lt_2_5":true,"no_liver_metastases":true,"pain_0_to_1":true,"psa_ng_ml":20,"treatment_enzalutamide":true},{"albumin_g_dl":4,"alp_below_uln":true,"bone_mets_lt_10":true,"hemoglobin_g_dl":13,"ldh_below_uln":true,"months_since_diagnosis":60,"nlr_lt_2_5":true,"no_liver_metastases":true,"pain_0_to_1":true,"psa_ng_ml":20,"treatment_enzalutamide":true}]},"method":"POST","type":"http"},"output_schema":{"$schema":"https://json-schema.org/draft/2020-12/schema","properties":{"input":{"additionalProperties":false,"properties":{"body":{"additionalProperties":false,"properties":{"items":{"items":{"properties":{"albumin_g_dl":{"description":"Serum albumin in g/dL (1.0-6.5). Armstrong 2018 Table 1: continuous, HR 0.71 per g/dL. magent does not assay albumin.","type":"number"},"alp_below_uln":{"description":"Alkaline phosphatase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus ≥ULN) has HR 0.79. magent does not assay ALP or apply ULN.","type":"boolean"},"bone_mets_lt_10":{"description":"Fewer than 10 bone metastases as assigned by the caller (true or false). Table 1: true (<10 versus ≥10) has HR 0.68. magent does not read bone scans.","type":"boolean"},"hemoglobin_g_dl":{"description":"Hemoglobin in g/dL (3.0-22.0). Table 1: continuous, HR 0.85 per g/dL. magent does not assay hemoglobin.","type":"number"},"ldh_below_uln":{"description":"Lactate dehydrogenase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus ≥1×ULN) has HR 0.67. magent does not assay LDH or apply ULN.","type":"boolean"},"months_since_diagnosis":{"description":"Time from diagnosis to randomization in months (0-720). Table 1: continuous, HR 0.997 per month. magent does not date the interval.","type":"number"},"nlr_lt_2_5":{"description":"Neutrophil-to-lymphocyte ratio <2.5 as assigned by the caller (true or false). Table 1: true (<2.5 versus ≥2.5) has HR 0.69. magent does not compute NLR from counts.","type":"boolean"},"no_liver_metastases":{"description":"No liver metastases as assigned by the caller (true or false). Table 1 pattern of spread: true (no liver metastases versus any liver metastases) has HR 0.49. magent does not read imaging.","type":"boolean"},"pain_0_to_1":{"description":"Pain score 0-1 versus ≥2 on the paper's linear scale, as assigned by the caller (true or false). Table 1: true (0-1 versus ≥2) has HR 0.77. magent does not assign pain scores.","type":"boolean"},"psa_ng_ml":{"description":"Baseline PSA in ng/mL (0.1-10000). Table 1: continuous log_e PSA, HR 1.23 per ln(ng/mL). magent does not assay PSA.","type":"number"},"treatment_enzalutamide":{"description":"true if the PREVAIL treatment term is enzalutamide, false if placebo. Table 1: true (enzalutamide versus placebo) has HR 0.68. Not a dose or treatment order.","type":"boolean"}},"required":["albumin_g_dl","alp_below_uln","bone_mets_lt_10","hemoglobin_g_dl","ldh_below_uln","nlr_lt_2_5","pain_0_to_1","no_liver_metastases","psa_ng_ml","months_since_diagnosis","treatment_enzalutamide"],"type":"object"},"maxItems":25,"minItems":1,"type":"array"}},"required":["items"],"type":"object"},"headers":{"additionalProperties":{"type":"string"},"type":"object"},"method":{"const":"POST","type":"string"},"type":{"const":"http","type":"string"}},"required":["type","method"],"type":"object"},"output":{"properties":{"example":{"type":"object"},"type":{"type":"string"}},"required":["type"],"type":"object"}},"required":["input"],"type":"object"},"history":[{"day":"2026-09-28","reachable":true,"status":402,"valid_402":true,"asked_usdc":0.007,"price_match":false,"latency_ms":305,"error":null}],"description_full":"Armstrong 2018 PREVAIL Cox linear predictor for overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer from albumin, ALP versus ULN, bone metastases under 10, hemoglobin, LDH versus ULN, NLR under 2.5, pain 0-1, liver metastases, ln(PSA), months from diagnosis, and enzalutamide versus placebo. Table 1 HRs as ln(HR). Not a 1-/2-/3-year OS percent (no published S0). magent does not read bone scans. Not a dose or treatment order.","last_updated":"2026-09-28T13:55:07.755Z","schemes":["exact"]}